TY - JOUR
T1 - Neurosarcoidosis
AU - Aksamit, Allen
N1 - Funding Information:
Technical assistance from S. K. Ichiki, C. L. Valencia, and E. N. Okazaki, and technical discussion with the late J. H. Becker, are acknowledged. This work was supported by Rome Air Development Center and currently is supported by a Lockheed Missiles & Space Company, Inc., Research & Development Division program.
PY - 2008/2
Y1 - 2008/2
N2 - Involvement of the nervous system by sarcoidosis is defined by pathologic proof either directly in the nervous system or systemically with appropriate findings consistent with sarcoidosis on neuroimaging and spinal fluid examinations. CNS sarcoidosis can present without systemic manifestations. Chronic meningitis is the most common clinical presentation, but cranial neuropathy, myelopathy, peripheral neuropathy, and myopathy are all possible. MRI imaging and gadolinium enhancement of the CNS is important for diagnosis. Spinal fluid abnormalities can be used as markers of disease activity during therapy. Biopsy of abnormal lymph node, lung, skin, meninges, or brain confirms the diagnosis. Conjunctival biopsy is a reasonable site for blind biopsy in CNS cases. Corticosteroids remain the mainstay of therapy, but the use of tumor necrosis factor α-antagonists shows significant promise in treatment of refractory CNS sarcoidosis cases.
AB - Involvement of the nervous system by sarcoidosis is defined by pathologic proof either directly in the nervous system or systemically with appropriate findings consistent with sarcoidosis on neuroimaging and spinal fluid examinations. CNS sarcoidosis can present without systemic manifestations. Chronic meningitis is the most common clinical presentation, but cranial neuropathy, myelopathy, peripheral neuropathy, and myopathy are all possible. MRI imaging and gadolinium enhancement of the CNS is important for diagnosis. Spinal fluid abnormalities can be used as markers of disease activity during therapy. Biopsy of abnormal lymph node, lung, skin, meninges, or brain confirms the diagnosis. Conjunctival biopsy is a reasonable site for blind biopsy in CNS cases. Corticosteroids remain the mainstay of therapy, but the use of tumor necrosis factor α-antagonists shows significant promise in treatment of refractory CNS sarcoidosis cases.
UR - http://www.scopus.com/inward/record.url?scp=40049110901&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40049110901&partnerID=8YFLogxK
U2 - 10.1212/01.CON.0000299992.09447.2b
DO - 10.1212/01.CON.0000299992.09447.2b
M3 - Review article
AN - SCOPUS:40049110901
SN - 1080-2371
VL - 14
SP - 181
EP - 196
JO - CONTINUUM Lifelong Learning in Neurology
JF - CONTINUUM Lifelong Learning in Neurology
IS - 1
ER -